What is the Corbus Pharmaceuticals Holdings, Inc. stock price forecast?

Corbus Pharmaceuticals Holdings, Inc. is currently trading at $7.91. View real-time AI analysis on Alpha Lenz.

What is Corbus Pharmaceuticals Holdings, Inc. insider trading activity?

View the latest insider trading data for Corbus Pharmaceuticals Holdings, Inc. on Alpha Lenz.

What is Corbus Pharmaceuticals Holdings, Inc.'s P/E ratio?

Corbus Pharmaceuticals Holdings, Inc.'s P/E ratio is -1.3.

Corbus Pharmaceuticals Holdings, Inc.

NASDAQ · CRBP

$7.91-3.44(-30.31%)Pre-market

Ask about Corbus Pharmaceuticals Holdings, Inc.'s future dividend policy...

Alpha Chat Insight

“Corbus Pharmaceuticals Holdings, Inc. trades at a P/E of -1.3 (undervalued) with modest ROE of -54.2%.”

Ask for details →

Company Overview

Corbus Pharmaceuticals Holdings, Inc. is a biopharmaceutical company that focuses on developing therapies for rare, chronic, and serious inflammatory and fibrotic diseases. At the core of its mission is the development of innovative small molecule drugs that target key pathways in inflammation and fibrosis. The company's lead product candidates are designed to modulate the immune system and have potential broad applications in autoimmune, fibrotic, and oncologic diseases. Corbus Pharmaceuticals primarily impacts the healthcare and life sciences sectors, emphasizing the treatment of conditions that currently have limited therapeutic options. In the financial market, Corbus Pharmaceuticals represents a segment of the biotechnology industry dedicated to addressing unmet medical needs, contributing to the advancement of specialized therapeutic approaches and offering potential medical breakthroughs.

CEODr. Yuval Cohen Ph.D.

Websitehttps://www.corbuspharma.com

SectorHealthcare

IndustryBiotechnology

Employees28

Company Statistics

FY 2025

Profile

$105.34MMarket Cap

$0.00Revenue

0.00Shares Out

28Employees

Margins

N/AGross

N/AEBITDA

N/AOperating

N/APre-Tax

N/ANet

Valuation

-1.34P/E

0.71P/B

N/AEV/Sales

-1.00EV/EBITDA

-1.63P/FCF

Growth (CAGR)

N/ARev 3Yr

N/ARev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-48.47%ROA

-54.18%ROE

-48.47%ROIC

Financial Health

$28.49MCash & Cash Equivalents

$-7.80MNet Debt

14.03%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Corbus Pharmaceuticals Holdings, Inc. trades at a P/E of -1.3 (undervalued) with modest ROE of -54.2%.”

Ask for details →

Frequently Asked Questions

Corbus Pharmaceuticals Holdings, Inc. (ticker: CRBP) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 28 employees. Market cap is $105M.

The current price is $7.91 with a P/E ratio of -1.34x and P/B of 0.71x.

ROE is -54.18%.